Global Fund - 2023 |
|
|---|---|
|
State Department |
|
|
Programme |
|
|
Sub Programme |
|
|
Allocation: |
KES 11,101,456.00 (R) |
Key Performance Indicators
Key Output |
KPI |
Target Yr (2023) |
Target Yr (2024) |
Target Yr (2025) |
|---|---|---|---|---|
|
Anti-Retroviral Therapy (ART) Supplies |
No. of patients receiving ART (Millions) |
1.3 |
- |
- |
|
Artemisinin-Based Combination Therapy (ACT) Supplies |
No. of People receiving ACT (Millions) |
4.8 |
- |
- |
|
Tuberculosis (TB) Supplies |
% of TB patients treated and tested for HIV |
100 |
- |
- |
Previous Year Allocations
Num |
Year |
Recurrent |
Development |
Total |
|---|---|---|---|---|
|
1 |
KES 22,520,960.00 |
KES 0.00 |
KES 22,520,960.00 |
|
|
2 |
KES 11,101,456.00 |
KES 0.00 |
KES 11,101,456.00 |
|
|
3 |
KES 6,099,626.00 |
KES 0.00 |
KES 6,099,626.00 |
|
|
4 |
KES 6,269,135.00 |
KES 0.00 |
KES 6,269,135.00 |
Funds disbursed to MDAs as a percentage of the external resources mobilized: 100
KES 240,262,679.00
(2023)
No. of feasibility studies conducted: 2
KES 61,000,000.00
(2023)